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OBJECTIVES: According to a report from the Rarer Cancers Foundation of England,
within the first six months of the launch of the Cancer Drugs Fund in England, only
£ 27,437,466 were used while the total amount allocated for the same period was
£50,000,000. This means that only a 56% of allocated funds for that period were
used. In a health system that restricts access to those oncological treatments that
have not shown to be cost-effective or have not been assessed by NICE a more
optimal use of the available funds would have been expected. In this study the
authors try to explore and determine the possible underlying reasons for the ob-
served underspent of allocated budget within the Cancer Drugs Fund in England
from October 2010 to March 2011. METHODS: Interviews were conducted across
different SHAs (Strategic Health Authorities) in England (n5) in 2011. A specific
questionnaire was designed to conduct this research RESULTS:Majority of respon-
dents mentioned delays in application for drug funding, miscalculation of expected
number of application by clinicians, among other reasons for underspent of Cancer
Drugs Fund CONCLUSIONS: SHAs should make sure that funds are properly allo-
cated and used in the benefit of patients and no application should be rejected in
the basis of an economic reason but just on pure clinical reasons
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OBJECTIVES: Analyzing the cancer incidence and TNM – classification is done by
national statistic in high spatial resolution, but no detailed data regarding pre-
existing illnesses and treatment pathways are gathered. That is why these prob-
lems are focused on using billing data from extramural and intramural anony-
mised patients datasets extended by drug prescription information. METHODS:
Starting with anonymized single person spatio-temporal hospital data including
diagnoses coded by ICD10, medical attendance data and patient identity key a
pre-selection is realized. In the next step the intramural patient history is focused
on, detecting the first indicated hospitalization. Afterwards criteria for the number
of reuptakes as well as for exclusion of cases (filtering not new diseases) are defined
based on the intramural patient history. Analyzing cancer indicated drug admin-
istration and drug prescription the year before the first hospitalization, knowledge
about risk groups is collected and evaluated. Additionally the probability of surviv-
ing regarding different treatment courses is measurable. These calculations are
done exemplary. RESULTS: Comparing the incidences calculated out of casemix
datasets for liver cancer, lung cancer and mamma carcinoma high accordance
comparing to cancer registry of Austria is observed. In case of liver cancer the
overall deviation is 14 cases per year; equal to a difference of 1.5 percent. In case of
mamma carcinoma 4882 detected new infections in control year 2007 are faced
with 4833 new cancer diseases registered by national statistics. CONCLUSIONS:
Using detailed single person spatio-longitudinal billing datasets in combination
with extended search strategies using exclusion criteria based on expert knowl-
edge as well as data structure information and modeling skills, highly reliable
datasets are edited. The analyzed background knowledge can be used in modern
dynamical simulation models producing reliable results.
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OBJECTIVES: European payer authorities reimburse the administration of antican-
cer agents for mNSCLC patients according to diverging tariffs and varying codes.
This poses the question of whether there is the need for a sensitivity analysis of
administration costs in health economic models when applied in France, Germany,
Italy, Spain, and the UK. METHODS: Two systematic literature reviews of the bib-
liographic database Medline were performed in order to identify relevant publica-
tions (of year 2000) on administration costs of chemotherapy for the treatment of
NSCLC. The review was supplemented by a search in the databases of the Cochrane
Library, EMA-EPAR, and ClinicalTrial.GOV. In addition, treatment guidelines, reim-
bursement databases, and national reimbursement tariffs were hand-searched.
Semi-structured interviews with expert oncologists were completed. Data extrac-
tion and evidence synthesis from these sources formed the basis of this evaluation.
RESULTS: Twenty-three manuscripts, 108 phase III study protocols, 6 EMA-labels,
and 12 European treatment guidelines were included in the analysis. The ten
NSCLC antineoplastic drugs mentioned in the ESMO and NCCN guidelines cover a
wide set of administration patterns with respect to 1st or 2nd line monotherapy,
combination therapy, and mono-or combination-maintenance therapy. The treat-
ment schedules vary in dose per application, composition per cycle, and number of
cycles. The main tariff for France is GHS 9606/GHM 28Z07Z (€386), for Germany
daycase DRG 71B (€720) and several separate agreements (“Onkologievereinba-
rung”) and for the UK daycase HRG SB97ZSB13Z (£399). For Italy and Spain the
actual DRG values vary tremendously, for instance in Italy for DRG410 (€310 for
Emilia Romagna vs. €40 for Basilicata), and in Spain C.6 for Galicia (€170) or 1.7.2.2
for Asturia (€149). CONCLUSIONS: The difference in treatment schedules in com-
bination with the variation in national administration tariffs shows the importance
of a sensitivity analysis when conducting a health economic analysis of NSCLC
administration costs in Europe.
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OBJECTIVES: In January 2009, the National Institute for Health and Clinical Excel-
lence (NICE) adopted an evaluation process for life-extending end-of-life treat-
ments. For eligible drugs, QALYs are weighted to favour the incremental cost-
utility ratios (ICUR). Also, patient access scheme (PAS, pricing agreements) are
sometimes established between the NHS and drug manufacturers to lower the
economic impact of costly drugs. The purpose of this study was to document the
effects of the end-of-life evaluation process (EOL) on anticancer drugs listing
recommendations. METHODS: NICE website was searched to identify published
technology appraisal guidances of anticancer drugs issued between January 2009
and May 2011. We documented EOL and PAS status, the listing recommendation
and the supporting ICURs. Positive and negative recommendations were stratified
by EOL and PAS status. RESULTS:We retrieved 32 recommendations among which
50% were approvals. The proportion of accepted drugs tends to be higher among
those evaluated with the EOL (9/16; 56%, p0,8). The ICURs of positive recommen-
dations associated with drugs not eligible or not considered for the EOL were
mostly comprised between 20,000£/QALY and 30,000£/QALY gained. On the other
hand, ratios of positive recommendations for drugs eligible to the EOL were higher
and varied from 30,350£/QALY to 54,366£/QALY gained. Among drugs evaluated
with the EOL, the proportion of accepted drugs analysed with PAS (6/9; 67%, p0,51)
tends to be higher than for drugs accepted without PAS. CONCLUSIONS: Despite
the small number of evaluations since its implementation, we observed with the
EOL a higher ICUR threshold that may have led NICE to recommend to list more
anticancer drugs that it would have been without the EOL. When the EOL was
considered, PAS also seems to have contributed to a higher rate of positive listing.
These findings have raised questions about the economic evaluation of anticancer
drugs in Canada.
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OBJECTIVES: To understand relative price differential for cancer drugs in the US
and the UK. Develop implications for pricing strategy and patient access for cancer
drugs. METHODS: Ten branded cancer drugs were selected and their prices for
similar dose and packaging were compared in the US and the UK. Prices were
analyzed for the end of 2010 and early 2011. Historical exchange rates were used to
convert British pounds to US dollars. Relative price discount was calculated for all
selected cancer drugs. KOLs and payers were interviewed to understand current
and future implications of this price differential. RESULTS: The median price dis-
count for selected ten branded cancer drugs in the UK versus the US was50%. The
range of discount for 10 branded cancer drugs was 27%-61%. The price discount for
oral small molecule drugs was higher than for biologics (55% versus 45%). Since UK
is one of the few remaining free pricing markets in Europe, other European markets
are likely to have even higher discounts relative to the prices in the United States.
Due to rising coinsurance of speciality products, US cancer patients bear signifi-
cantly higher cost than patients in the UK. KOL and payer interviews suggest US
pricing trends for cancer drugs are unlikely to be sustained at this level in the
future. CONCLUSIONS: US cancer drug prices are significantly higher than the
prices in the UK. This price differential is unlikely to be sustained in the future.
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OBJECTIVES: Objective of this study was to assess reimbursement outcomes and
patient access to oncology drugs in Croatia. National Institute of Clinical Excellence
(NICE) cancer guidelines and National Comprehensive Cancer Network (NCCN)
guidelines were used as benchmark. NICE is known for being committed to com-
plying with legal obligations on equity and human rights, conducting their work
based on identified cost effectiveness thresholds and known to be restrictive in
their recommendations. On the other hand, NCCN professional guidelines are key
international guidelines for oncology professionals which have been accepted and
followed worldwide. METHODS: Reimbursement processes, specific indications
and restrictions for 23 studied cancer drugs, ATC L01 class (antineoplastic agents)
have been analyzed and compared to UK NHS funding and reimbursement recom-
mendations given through NICE cancer guidelines as well as recommendations
given through NCCN guidelines. RESULTS: Studied cancer drugs were used for the
treatment of 14 different tumor locations: breast, colon, lung, leukemia, renal,
GIST, ovary, lymphoma, glioblastoma, prostate, liver, gastric, myeloma. Among 57
registered indications, Croatian Health Insurance Fund has in total reimbursed 43
(75%) while NICE has issued positive recommendations for only 35 (60%). On the
other hand, all investigated drugs and relevant indications except of one partially
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